Want to see AVBP full AI Analyst Report?
AVBP Stock Chart & Stats
$31.14
-$0.27(-0.85%)
At close: 4:00 PM EDT
$31.14
-$0.27(-0.85%)
Day’s Range― - ―
52-Week Range$11.36 - $35.83
Previous CloseN/A
Volume264.76K
Average Volume (3M)1.70M
Market Cap
$1.04B
Enterprise Value$1.28B
Total Cash (Recent Filing)$373.12M
Total Debt (Recent Filing)$351.00K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 18, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.68
Shares Outstanding49,307,728
10 Day Avg. Volume1,425,062
30 Day Avg. Volume1,696,040
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.82
Forecast
1Y Price Target
$26.08Price Target Upside-16.24% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-4.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong, Lightly Levered Balance SheetExtremely low leverage and substantial asset growth provide financial flexibility for continued clinical development. This reduces near-term balance-sheet pressure and supports investment in the pipeline, although the company still needs future revenue or funding to sustain operations over the longer term.
Promising Firmonertinib Phase 1b DataThe reported clinical activity in an underserved EGFR PACC-mutant NSCLC subgroup supports firmonertinib’s differentiated development rationale. Durable responses, progression-free survival and intracranial activity could strengthen the case for the Phase 3 ALPACCA study and future targeted-market positioning.
Pipeline Expansion Through ARR-002Advancing a second ADC into the clinic broadens ArriVent beyond its lung-cancer programs and creates another potential source of long-term value. The dual-target design and entry into gynecologic cancers expand the addressable opportunity while diversifying clinical development exposure.
Bears Say
No Revenue And Widening LossesArriVent has not yet established a commercial revenue base to offset its research and development spending. Widening losses increase the distance to self-funded operations and make future financial performance highly dependent on successful clinical development, commercialization or partnership economics.
Persistent Cash Burn And Funding DependenceSustained negative operating and free cash flow means clinical execution consumes substantial capital before revenue can begin. Although TTM burn improved from 2025, continued spending leaves ArriVent dependent on its existing resources and potential external funding to advance programs.
Phase 3 FURVENT Primary-endpoint MissThe primary-endpoint failure weakens the evidence base for firmonertinib in the first-line EGFR exon 20 insertion setting and increases development uncertainty. Despite favorable secondary measures and safety, the result may complicate the U.S. path and broader lead-asset strategy.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $11.36 and its highest was $35.83 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $1.04B.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 25 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Aug 12, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.987 by -$0.063.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Overvalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -1.05.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 49,307,728 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.987. Following the earnings report the stock price went down -4.641%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ArriVent BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.08 (-16.24% Downside)
$26.08 (-16.24% Downside)
Blogger Sentiment
Bullish
AVBP Sentiment 60%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.4%
Last 30 Days ▲ 14.6%
Last 30 Days ▲ 14.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.08%
12-Months-Change
Fundamentals
Return on Equity
-50.26%
Trailing 12-Months
Asset Growth
46.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$26.08
▼(-16.24% Downside)
Technical Analysis
Verastem
―
Kura Oncology
―
Zentalis Pharmaceuticals
―
Cullinan Management
―
Pyxis Oncology
―
Ownership Overview
9.04% Insiders
11.43% Mutual Funds
0.28% Other Institutional Investors
66.52% Public Companies and
Individual Investors